Comprehensive profiles for every peptide covered on this site. Each page includes mechanism of action, FDA/regulatory status, clinical trial data, studied dosing ranges, side effects, and a full reference list with links to published research.
These peptides or peptide-based drugs have received FDA approval for specific indications. Approval is limited to the stated indication, off-label use is a separate consideration.
Growth hormone-releasing hormone analog approved for HIV-associated lipodystrophy. Stimulates endogenous pituitary GH release. Only FDA-approved indication is reduction of excess abdominal fat in HIV patients.
FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts on melanocortin-4 receptors in the CNS, a unique mechanism distinct from vascular-acting agents.
Peptides studied for their potential roles in wound healing, tissue regeneration, and injury recovery. None in this category are FDA-approved for these applications.
A 15-amino-acid peptide derived from human gastric juice. Extensively studied in preclinical models for tissue repair, gut healing, and anti-inflammatory effects. FDA Category 2 listed (Sept 2023). Only ~3 small published human studies.
A synthetic fragment of Thymosin Beta-4, a naturally occurring protein involved in cell migration, blood vessel formation, and wound healing. Primarily studied in preclinical and veterinary research contexts.
A naturally occurring copper-binding tripeptide found in human plasma. Studied for skin regeneration, collagen synthesis, wound healing, and anti-aging applications. Plasma levels decline significantly with age.
FDA-approved for interstitial cystitis (bladder pain). A semi-synthetic sulfated polysaccharide studied for joint health and osteoarthritis applications in veterinary and human research.
Peptides that stimulate the body's natural growth hormone production through GHRH receptor agonism or ghrelin receptor activation.
The most commonly studied GH secretagogue combination. Research suggests 2-3x GH elevation versus single-peptide use via complementary pituitary stimulation pathways. Clinical development was discontinued before completing full efficacy trials.
A modified 29-amino acid analog of growth hormone-releasing hormone (GHRH). Stimulates pituitary GH release with a short half-life (~30 min), producing pulsatile GH secretion that more closely mimics natural physiology.
A selective growth hormone secretagogue that acts on ghrelin receptors. Unlike GHRP-6 or GHRP-2, ipamorelin does not significantly elevate cortisol or prolactin at studied doses, giving it a cleaner selectivity profile.
A modified fragment of the C-terminus of human growth hormone (amino acids 176-191). Studied for its potential lipolytic (fat-burning) effects without the growth-promoting or diabetogenic effects of full GH.
Peptides studied for immune modulation, anti-inflammatory signaling, and thymic function.
A 28-amino acid thymic peptide approved in over 30 countries (not FDA-approved in the US) for hepatitis B and C and as an immune adjuvant. Studied for immune restoration, vaccine enhancement, and anti-tumor effects.
A tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH). Studied for anti-inflammatory effects via NF-κB signaling pathway inhibition. Research interest in gut inflammation and mucosal healing applications.
Peptides studied for cognitive enhancement, neuroprotective effects, and neurological function.
A synthetic analog of the immunomodulatory peptide tuftsin, developed at the Institute of Molecular Genetics (Russia). Approved in Russia as an anxiolytic. Studied for anti-anxiety effects, cognitive enhancement, and immune modulation.
A synthetic heptapeptide analog of ACTH(4-10), developed in Russia and approved there for stroke recovery and cognitive disorders. Studied for neuroprotection, BDNF modulation, and cognitive enhancement.
A small peptide derivative of angiotensin IV. Studied as an HGF/c-Met signaling agonist with potential procognitive effects. Early-stage research only, described as extremely potent in animal models of cognitive decline.
Peptides studied for anti-aging, telomere biology, mitochondrial function, and cellular senescence.
A synthetic tetrapeptide studied for its potential to activate telomerase and influence pineal gland function. Based on the Epithalamin research by Khavinson. Primarily preclinical data; limited human trial evidence.
A mitochondria-derived peptide described as an "exercise mimetic." Studied for AMPK activation, metabolic regulation, insulin sensitivity, and exercise performance. Discovered in 2015 by Dr. Pinchas Cohen's lab at USC.
A mitochondria-targeting tetrapeptide that stabilizes cardiolipin in the inner mitochondrial membrane. In clinical trials for Barth syndrome and primary mitochondrial myopathy. Studied for age-related mitochondrial dysfunction.
A coenzyme essential to cellular metabolism, DNA repair, and sirtuin activation (included for completeness as a peptide-adjacent compound). NAD+ levels decline with age, driving interest in supplementation and IV protocols.
Peptides studied for sexual function, sleep architecture, and hypothalamic-pituitary hormonal signaling.
Master regulator of the reproductive hormone axis. Drives GnRH release and downstream LH/FSH/sex steroid production. Studied at Imperial College London in human trials for HSDD (both sexes), hypothalamic amenorrhea, male hypogonadism, and IVF applications.
A nonapeptide first isolated in 1977 from rabbit cerebral venous blood during induced sleep. Studied for promotion of slow-wave (delta) sleep, normalization of disrupted sleep architecture, HPA axis modulation, and adjunctive use in chronic pain and withdrawal-related sleep disruption.
Pre-mixed peptide combinations commonly referenced in the research community. Important: while individual components may have published research, these specific blends have NOT been studied as combined formulations in clinical trials.
The most widely recognized peptide "stack." Combines two tissue-repair peptides with complementary mechanisms. BPC-157 (angiogenesis, nitric oxide) and TB-500 (cell migration, actin regulation). No published research on the specific combination.
A skin and tissue-focused combination. GHK-Cu is the primary skin-targeted component (collagen synthesis, elastin production), supported by BPC-157 and TB-500 for tissue repair. No published research on this specific blend.
Adds KPV (anti-inflammatory tripeptide, fragment of α-MSH) to the GLOW base. KPV inhibits NF-κB signaling, providing an anti-inflammatory component. No published research on this specific blend formulation.